Celecoxib

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Colorectal Adenoma

Conditions

Colorectal Adenoma

Trial Timeline

Feb 1, 2001 → May 1, 2007

NCT ID

NCT00141193

About Celecoxib

Celecoxib is a phase 3 stage product being developed by Pfizer for Colorectal Adenoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00141193. Target conditions include Colorectal Adenoma.

What happened to similar drugs?

15 of 20 similar drugs in Colorectal Adenoma were approved

Approved (15) Terminated (3) Active (4)

✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved

✅Cetuximab (EGFR inhibitor) + Bevacizumab + Irinotecan (CPT-11) + Oxaliplatin + Leucovorin and 5-FU + CapecitabineMerckApproved

✅5-FU based doublet chemotherapy + bevacizumabRocheApproved

✅capecitabine [Xeloda]RocheApproved

✅5-Fluorouracil + Bevacizumab + Irinotecan + OxaliplatinRocheApproved

✅Oxaliplatin + Capecitabine + Bevacizumab + Leucovorin + 5-Fluouracil + IrinotecanRocheApproved

✅CapecitabineRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00976716	Phase 3	Completed	Sep 1, 2009	Nov 1, 2009	Pain
NCT00585156	Phase 1	Terminated	Jun 1, 2008	Sep 1, 2008	Bone Ingrowth
NCT00474773	Pre-clinical	Completed	Jun 1, 2007	Dec 1, 2009	Pain Management
NCT00304317	Approved	Withdrawn	Mar 1, 2006	Aug 1, 2008	Ureteral Calculi
NCT00296127	Phase 1	Completed	Feb 1, 2006	Mar 1, 2006	Healthy Volunteers
NCT00151476	Pre-clinical	Terminated	Nov 1, 2004	Nov 1, 2008	Familial Adenomatous Polyposis (FAP)
NCT00163241	Phase 3	Terminated	Jun 1, 2004	Jan 1, 2006	Osteoarthritis
NCT00194090	Approved	Completed	Jun 1, 2004	Sep 1, 2005	Knee Osteoarthritis
NCT00633438	Approved	Completed	Jan 1, 2004	Jun 1, 2004	Arthroscopy
NCT00638807	Approved	Completed	Dec 1, 2003	Jul 1, 2004	Osteoarthritis, Knee
NCT00181532	Phase 2	Completed	May 1, 2003	Jan 1, 2008	Non Small Cell Lung Carcinoma
NCT00633386	Approved	Completed	Feb 1, 2003	Aug 1, 2003	Arthroscopy
NCT00136487	Phase 2/3	Completed	Oct 1, 2002	Sep 1, 2006	Prostate Cancer
NCT00141193	Phase 3	Completed	Feb 1, 2001	May 1, 2007	Colorectal Adenoma
NCT00036283	Phase 2	Completed	Nov 1, 2000	Apr 1, 2004	Precancerous Conditions

Competing Products

20 competing products in Colorectal Adenoma

See all competitors

Product	Company	Stage	Hype Score
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	35
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU	Eli Lilly	Phase 2	35
ZN-c3 + Encorafenib + Cetuximab	Zentalis Pharmaceuticals	Phase 1	11
ALIMTA + Oxaliplatin	Eli Lilly	Phase 2	35
eFT508 + Avelumab	eFFECTOR Therapeutics	Phase 2	25
Bevacizumab + Oxaliplatin + Capecitabine	Chugai Pharmaceutical	Phase 1/2	32
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + Capecitabine	Chugai Pharmaceutical	Phase 2	31
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOX	Chugai Pharmaceutical	Phase 2/3	38
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	35
CPT-11 and TS-1 + CPT-11, 5-FU and l-LV	Daiichi Sankyo	Phase 2/3	38
CPT-11 based regimens	Daiichi Sankyo	Pre-clinical	26
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)	Daiichi Sankyo	Phase 2	35
Tivantinib + Placebo + Cetuximab + Irinotecan	Daiichi Sankyo	Phase 1/2	32
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3W	Daiichi Sankyo	Phase 2	35
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
CS-1008 + irinotecan	Daiichi Sankyo	Phase 2	27
CS-7017 + Placebo	Daiichi Sankyo	Phase 2	27
Patritumab Deruxtecan	Daiichi Sankyo	Phase 2	27
CS-1008 + FOLFIRI	Daiichi Sankyo	Phase 1	29
DS-8273a + nivolumab	Daiichi Sankyo	Phase 1	21